Company research
Intellia Therapeutics, Inc.
CIK 1652130Updated Nov 14, 2026
SecurityNTLA · NASDAQ · equity
NTLA price & chart
Loading TradingView…
NASDAQ:NTLA on TradingView ↗About the company
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
In the news
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
The Credibility Filter Wall Street Uses to Sort Biotech Winners ↗
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation News provided by Shareholders Foundation, Inc. Apr 23, 2025, 09:50 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 23, 2025 /PRNewswire/ -- Sharehol ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by STATE STREET CORP regarding Intellia Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 925,275,000Source | 1,173,351,000Source | 857,164,000Source | 898,894,000Source | 1,191,536,000Source | 758,779,000Source | 986,163,000Source | 1,259,589,000Source | 842,127,000Source | 1,191,015,000Source | 1,300,977,000Source | 1,520,114,000Source |
| Property, Plant and Equipment, NetUSD | 20,421,000Source | 28,763,000Source | 15,058,000Source | 22,806,000Source | 30,273,000Source | 15,516,000Source | 25,123,000Source | 32,075,000Source | 17,671,000Source | 27,381,000Source | 32,760,000Source | 27,921,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 193,389,000Source | 120,495,000Source | 106,128,000Source | 156,172,000Source | 130,849,000Source | 134,697,000Source | 126,880,000Source | 171,979,000Source | 155,464,000Source | 189,182,000Source | 226,748,000Source | 523,506,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 11,050,000Source | 8,854,000Source | 7,321,000Source | 11,353,000Source | 12,329,000Source | 9,131,000Source | 10,504,000Source | 36,427,000Source | 9,468,000Source | 8,517,000Source | 36,456,000Source | 3,768,000Source |
| Assets, CurrentUSD | 581,941,000Source | 710,902,000Source | 527,832,000Source | 495,945,000Source | 757,211,000Source | 466,449,000Source | 551,392,000Source | 884,043,000Source | 527,711,000Source | 639,863,000Source | 998,330,000Source | 1,216,797,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 59,847,000Source | 43,934,000Source | 82,752,000Source | 24,941,000Source | 53,814,000Source | 81,332,000Source | 37,141,000Source | 56,322,000Source | 68,359,000Source | 29,831,000Source | 49,651,000Source | 20,407,000Source |
| Operating Lease, Right-of-Use AssetUSD | 117,883,000Source | 100,331,000Source | 85,954,000Source | 129,045,000Source | 105,412,000Source | 97,543,000Source | 137,979,000Source | 110,424,000Source | 105,955,000Source | 219,292,000Source | 115,375,000Source | 133,076,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 176,853,000Source | 210,736,000Source | 129,458,000Source | 183,639,000Source | 220,474,000Source | 137,840,000Source | 206,244,000Source | 223,452,000Source | 170,733,000Source | 319,059,000Source | 250,808,000Source | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 12,000Source | 10,000Source | 14,000Source | 10,000Source | 10,000Source | 12,000Source | 10,000Source | 10,000Source | 12,000Source | 10,000Source | 9,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,494,308,000Source | -2,048,502,000Source | -2,792,959,000Source | -2,392,984,000Source | -1,912,790,000Source | -2,686,325,000Source | -2,291,729,000Source | -1,765,815,000Source | -2,590,094,000Source | -2,177,400,000Source | -1,658,379,000Source | -1,177,187,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 990,000Source | 3,297,000Source | -1,030,000Source | 653,000Source | -1,155,000Source | -240,000Source | 1,057,000Source | -947,000Source | 1,032,000Source | 605,000Source | -2,258,000Source | -7,461,000Source |
| Stockholders' Equity Attributable to ParentUSD | 748,422,000Source | 962,615,000Source | 727,706,000Source | -715,255,000Source | 971,062,000Source | 620,939,000Source | 779,919,000Source | 1,036,137,000Source | 671,394,000Source | 871,956,000Source | 1,050,169,000Source | 1,235,584,000Source |
| Additional Paid in Capital, Common StockUSD | 3,241,728,000Source | 3,007,810,000Source | 3,521,681,000Source | 3,107,576,000Source | 2,884,997,000Source | 3,307,492,000Source | 3,070,581,000Source | 2,802,889,000Source | 3,260,444,000Source | 3,048,741,000Source | 2,710,797,000Source | 2,420,223,000Source |
| Liabilities and EquityUSD | 925,275,000Source | 1,173,351,000Source | 857,164,000Source | 898,894,000Source | 1,191,536,000Source | 758,779,000Source | 986,163,000Source | 1,259,589,000Source | 842,127,000Source | 1,191,015,000Source | 1,300,977,000Source | 1,520,114,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 93,726,000Source | 105,683,000Source | 79,392,000Source | 95,499,000Source | 105,090,000Source | 76,445,000Source | 112,593,000Source | 97,912,000Source | 103,884,000Source | 110,851,000Source | 115,208,000Source | 126,554,000Source |
| Operating Lease, Liability, CurrentUSD | 27,378,000Source | 19,177,000Source | 23,344,000Source | 26,990,000Source | 18,963,000Source | 19,095,000Source | 38,763,000Source | 18,763,000Source | 26,480,000Source | 20,246,000Source | 18,599,000Source | 16,685,000Source |
| Accounts Payable, CurrentUSD | 13,260,000Source | 13,145,000Source | 11,714,000Source | 9,802,000Source | 18,816,000Source | 18,800,000Source | 12,364,000Source | 13,689,000Source | 20,252,000Source | 14,589,000Source | 7,452,000Source | 5,154,000Source |
| Operating Lease, Liability, NoncurrentUSD | 70,588,000Source | 82,446,000Source | 50,066,000Source | 75,601,000Source | 87,332,000Source | 61,395,000Source | 80,490,000Source | 92,100,000Source | 66,849,000Source | 189,952,000Source | 96,747,000Source | 114,018,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 40,841,000Source | 51,206,000Source | 44,334,000Source | 41,553,000Source | 45,127,000Source | 37,920,000Source | 40,805,000Source | 43,276,000Source | 49,862,000Source | 55,355,000Source | 67,017,000Source | 60,876,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 2,400,000Source | 2,600,000Source | 2,100,000Source | 2,500,000Source | 2,202,000Source | 2,498,000Source | 9,767,000Source | 10,285,000Source | 8,976,000Source | 7,572,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,479,000Source | 21,840,000Source | 80,219,000Source | 154,273,000Source | 134,050,000Source | 91,400,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -337,000Source | 1,987,000Source | 951,000Source | -27,939,000Source | 32,688,000Source | 1,737,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,420,000Source | -1,869,000Source | 5,987,000Source | 6,800,000Source | 2,522,000Source | -4,584,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -117,346,000Source | -148,930,000Source | -394,736,000Source | -348,880,000Source | -394,086,000Source | -333,287,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 287,000Source | 287,000Source | 287,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 66,310,000Source | 94,328,000Source | 228,031,000Source | 125,567,000Source | -31,347,000Source | 160,309,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 79,000Source | 735,000Source | 1,129,000Source | 5,778,000Source | 13,985,000Source | 13,558,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 33,569,000Source | 0Source | 131,486,000Source | 185,747,000Source | 130,323,000Source | 582,955,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -17,467,000Source | -54,602,000Source | -35,219,000Source | -37,566,000Source | -295,110,000Source | 409,977,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 19,604,000Source | 39,619,000Source | 18,075,000Source | 22,036,000Source | 13,479,000Source | 21,840,000Source | 80,219,000Source | 154,273,000Source | 134,050,000Source | 91,400,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 10,541,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 3,439,000Source | -3,064,000Source | 329,000Source | 1,339,000Source | -904,000Source | -2,125,000Source | -899,000Source | -32,565,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -527,000Source | 76,000Source | -72,000Source | 162,000Source |
| General and Administrative ExpenseUSD | — | — | 30,512,000Source | 30,501,000Source | 37,824,000Source | 27,206,000Source | 34,843,000Source | 29,007,000Source | 119,800,000Source | 125,829,000Source | 116,497,000Source | 90,306,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -15,633,000Source | -11,079,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 6,714,000Source | 12,122,000Source | 5,797,000Source | 7,402,000Source | 5,205,000Source | 8,603,000Source | 29,195,000Source | 47,807,000Source | 49,832,000Source | 8,542,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 337,000Source | 4,452,000Source | -790,000Source | -404,000Source | -1,272,000Source | 452,000Source | 427,000Source | 731,000Source | 3,635,000Source | -1,637,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -101,324,000Source | -135,712,000Source | -106,634,000Source | -101,255,000Source | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,153,000Source | 9,058,000Source | 6,126,000Source | 8,741,000Source | 4,301,000Source | 6,478,000Source | 28,296,000Source | 15,242,000Source | 34,099,000Source | -16,022,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 194,600,000Source | — | 128,175,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 722,000Source | 5,862,000Source | 6,599,000Source | 14,517,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 6,600,000Source | 11,400,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,782,000Source | 9,111,000Source | 7,659,000Source | 14,245,000Source | 15,048,000Source | 16,627,000Source | 67,671,000Source | 57,877,000Source | 36,275,000Source | 52,121,000Source |
| Operating Income (Loss)USD | — | — | -111,477,000Source | -144,770,000Source | -112,760,000Source | -109,996,000Source | -100,532,000Source | -120,807,000Source | -440,990,000Source | -534,263,000Source | -515,291,000Source | -458,164,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,153,000Source | 9,058,000Source | 6,126,000Source | 8,741,000Source | 4,301,000Source | 6,478,000Source | 28,296,000Source | 15,242,000Source | 34,099,000Source | -16,022,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -101,324,000Source | -135,712,000Source | -106,634,000Source | -101,255,000Source | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.92Source | -1.34Source | -0.8Source | -0.98Source | -0.81Source | -1.1Source | -3.81Source | -5.25Source | -5.42Source | -6.16Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.92Source | -1.34Source | -0.8Source | -0.98Source | -0.81Source | -1.1Source | -3.81Source | -5.25Source | -5.42Source | -6.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 110,188,000Source | 101,002,000Source | 133,480,000Source | 103,732,000Source | 118,490,000Source | 103,500,000Source | 108,376,000Source | 98,849,000Source | 88,770,000Source | 76,972,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 110,188,000Source | 101,002,000Source | 133,480,000Source | 103,732,000Source | 118,490,000Source | 103,500,000Source | 108,376,000Source | 98,849,000Source | 88,770,000Source | 76,972,000Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 125,259,000Source | 153,881,000Source | 120,419,000Source | 124,241,000Source | 115,580,000Source | 137,434,000Source | 508,661,000Source | 592,140,000Source | 551,566,000Source | 510,285,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 3,439,000Source | -3,064,000Source | 329,000Source | 1,339,000Source | -904,000Source | -2,125,000Source | -899,000Source | -32,565,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 30,512,000Source | 30,501,000Source | 37,824,000Source | 27,206,000Source | 34,843,000Source | 29,007,000Source | 119,800,000Source | 125,829,000Source | 116,497,000Source | 90,306,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -15,633,000Source | -11,079,000Source |
| Investment Income, InterestUSD | — | — | 6,714,000Source | 12,122,000Source | 5,797,000Source | 7,402,000Source | 5,205,000Source | 8,603,000Source | 29,195,000Source | 47,807,000Source | 49,832,000Source | 8,542,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
| Research and Development ExpenseUSD | — | — | 94,747,000Source | 123,380,000Source | 82,595,000Source | 97,035,000Source | 80,737,000Source | 108,427,000Source | 388,861,000Source | 466,311,000Source | 435,069,000Source | 419,979,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 6,600,000Source | 11,400,000Source |
Filing attachments
ntla-ex99_1.htm · 8-K/A · 2026-11-13
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1 This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements about Intellia’s beliefs and expectations regarding: our ability to successfully develop and commercialize lonvoguran ziclumeran (“lonvo-z”), …
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-11-12
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1 This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements about Intellia’s beliefs and expectations regarding: our ability to successfully develop and commercialize lonvoguran ziclumeran (“lonvo-z”), …
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 - Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM - Existing cash resourc…
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) • FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 • Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., September 8, 2026 -- Intellia Therapeutics, Inc. (Nasd…
Read attachment ↗d110798dex991.htm · 8-K · 2026-09-04
EX-99.1 2 d110798dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points CAMBRIDGE, Mass., September 4, 2026 - Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing …
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine - Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027 - Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expe…
Read attachment ↗